Medical devices, healthcare technology and the business of care
PMA approval · P120019

COBAS EGFR MUTATION TEST

Roche · Decision date May 14, 2013

MEDTECHLEDGER EXPLANATIONP120019

What did the FDA approve?

FDA PMA P120019 was approved for the cobas® EGFR Mutation Test. The record describes the device as a real-time PCR assay for qualitative detection of EGFR exon 19 deletions and exon 21 (L858R) substitution mutations in DNA from formalin-fixed paraffin-embedded human NSCLC tumor tissue. That is the original PMA scope stated here; the source does not describe a supplement or any change to that scope.

The statement also gives the intended-use wording: the test is an aid in selecting patients with metastatic NSCLC for whom Tarceva® (erlotinib) is indicated. It does not provide clinical performance data, trial results, or a broader indication beyond that language, so those points remain unknown from this record.

FDA approval order statement

APPROVAL FOR THE COBAS EGFR MUTATION TEST. THE COBAS EGFR MUTATION TEST IS A REAL-TIME PCR TEST FOR THE QUALITATIVE DETECTION OF EXON 19 DELETIONS AND EXON 21 (L858R) SUBSTITUTION MUTATIONS OFTHE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) GENE IN DNA DERIVED FROM FORMALIN-FIXED PARAFFIN-EMBEDDED (FFPET) HUMAN NON-SMALL CELL LUNG CANCER (NSCLC) TUMOR TISSUE. THE TEST IS INTENDED TO BE USED AS AN AID IN SELECTING PATIENTS WITH METASTATIC NSCLC FOR WHOM TARCEVA (ERLOTINIB), AN EGFR TYROSINE KINASE INHIBITOR (TK1), IS INDICATED. SPECIMENS ARE PROCESSED USING THE COBAS DNA SAMPLE PREPARATION KIT FOR MANUAL SAMPLE PREPARATION AND THE COBAS Z 480 ANALYZER FOR AUTOMATED AMPLIFICATION AND DETECTION.
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
May 14, 2013

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P120019
Regulatory pathway
Premarket approval application
Applicant
Roche
Product code
OWD
Decision code
APPR
Decision date
May 14, 2013
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Somatic gene mutation detection system.

Applicant
Roche
Product code
OWD
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P120019 received

    Application receipt date recorded by FDA.

  2. P120019 · FDA decision

    APPR

  3. P120019/S044 · Related supplement

    cobas EGFR Mutation Test, v2.0

  4. P120019/S045 · Related supplement

    Roche cobas EGFR Mutation Test, v2.0

Timeline entries are records held by MedtechLedger for P120019. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P120019

Product / regulatory recordCompanyPathwayDecision dateSource
RochePMA supplementOct 27, 2026FDA
RochePMA supplementNov 4, 2026FDA

Explore the linked device profile

Other records with product code OWD

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Roche Molecular System, Inc.PMA supplementOct 27, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
4300 Hacienda Dr., P.O. Box 9002, Peasanton, CA, 94588

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records